| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $289,100 | 1 | 2 |
Sells | $24,361,031 | 42 | 98 |
| Smiley Joshua L | See Remarks | 1 | $289,100 | 3 | $773,083 | $-483,983 |
| Morrison Scott W | director | 0 | $0 | 1 | $715,086 | $-715,086 |
| Amado Rafael | See Remarks | 0 | $0 | 5 | $779,230 | $-779,230 |
| Chen Yajing | Chief Financial Officer | 0 | $0 | 8 | $817,598 | $-817,598 |
| Lis William | director | 0 | $0 | 2 | $987,445 | $-987,445 |
| Edmondson Frazor Titus III | Chief Legal Officer | 0 | $0 | 7 | $1.41M | $-1.41M |
| Du Ying | Chairperson & CEO | 0 | $0 | 16 | $18.88M | $-18.88M |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Over the last 12 months, insiders at Zai Lab Limited have bought $289,100 and sold $24.36M worth of Zai Lab Limited stock.
On average, over the past 5 years, insiders at Zai Lab Limited have bought $238,870 and sold $53.3M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Smiley Joshua L (See Remarks) — $289,100.
The last purchase of 10,000 shares for transaction amount of $289,100 was made by Smiley Joshua L (See Remarks) on 2025‑09‑10.
| 2025-12-31 | Sale | Amado Rafael | See Remarks | 10,787 0.0096% | $17.43 | $188,039 | +4.25% | |
| 2025-12-16 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 8,651 0.0079% | $17.14 | $148,278 | +7.06% | |
| 2025-11-21 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 14,328 0.0128% | $19.78 | $283,408 | -8.24% | |
| 2025-11-03 | Sale | Chen Yajing | Chief Financial Officer | 240 0.0002% | $26.83 | $6,439 | -30.39% | |
| 2025-10-02 | Sale | Chen Yajing | Chief Financial Officer | 456 0.0004% | $34.25 | $15,617 | -42.33% | |
| 2025-09-10 | Smiley Joshua L | See Remarks | 10,000 0.0093% | $28.91 | $289,100 | -29.68% | ||
| 2025-08-18 | Sale | Smiley Joshua L | See Remarks | 6,641 0.0061% | $36.24 | $240,643 | -39.11% | |
| 2025-08-18 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 1,883 0.0017% | $36.24 | $68,232 | -39.11% | |
| 2025-08-15 | Sale | Chen Yajing | Chief Financial Officer | 1,438 0.0013% | $35.42 | $50,932 | -39.15% | |
| 2025-08-13 | Sale | Du Ying | Chairperson & CEO | 46,387 0.042% | $35.47 | $1.65M | -38.77% | |
| 2025-08-12 | Sale | Du Ying | Chairperson & CEO | 50,000 0.0449% | $34.25 | $1.71M | -36.23% | |
| 2025-08-11 | Sale | Du Ying | Chairperson & CEO | 50,000 0.0454% | $34.64 | $1.73M | -36.86% | |
| 2025-08-08 | Sale | Du Ying | Chairperson & CEO | 50,000 0.045% | $34.74 | $1.74M | -37.39% | |
| 2025-08-08 | Sale | Amado Rafael | See Remarks | 3,000 0.0027% | $35.00 | $105,000 | -37.39% | |
| 2025-08-08 | Sale | Chen Yajing | Chief Financial Officer | 4,096 0.0036% | $34.01 | $139,305 | -37.39% | |
| 2025-07-02 | Sale | Du Ying | Chairperson & CEO | 7,072 0.0064% | $35.23 | $249,147 | -21.05% | |
| 2025-06-30 | Sale | Du Ying | Chairperson & CEO | 6,918 0.0064% | $35.52 | $245,727 | -19.10% | |
| 2025-06-26 | Sale | Du Ying | Chairperson & CEO | 23,669 0.0214% | $36.13 | $855,208 | -21.53% | |
| 2025-06-26 | Sale | Edmondson Frazor Titus III | Chief Legal Officer | 5,877 0.0053% | $36.13 | $212,348 | -21.53% | |
| 2025-06-26 | Sale | Chen Yajing | Chief Financial Officer | 2,675 0.0024% | $36.13 | $96,653 | -21.53% |
| Du Ying | Chairperson & CEO | 536962 0.4852% | $10.76M | 0 | 35 | |
| Smiley Joshua L | See Remarks | 86604 0.0783% | $1.74M | 5 | 5 | <0.0001% |
| Amado Rafael | See Remarks | 52391 0.0473% | $1.05M | 0 | 10 | |
| Lis William | director | 35106 0.0317% | $703,524.24 | 0 | 5 | |
| Morrison Scott W | director | 23702 0.0214% | $474,988.08 | 0 | 1 | |
| Edmondson Frazor Titus III | Chief Legal Officer | 19086 0.0172% | $382,483.44 | 0 | 15 | |
| Chen Yajing | Chief Financial Officer | 17444 0.0158% | $349,577.76 | 0 | 15 | |
| Fu Tao | President & COO | 77500 0.07% | $1.55M | 0 | 9 | |
| DIEKMAN JOHN D | director | 67615 0.0611% | $1.36M | 0 | 4 | |
| Reinhart Harald | See Remarks | 62619 0.0566% | $1.25M | 0 | 18 | |
| Chen Kai-Xian | director | 60778 0.0549% | $1.22M | 0 | 2 | |
| Cho William Ki Chul | Chief Financial Officer | 50000 0.0452% | $1M | 0 | 2 | |
| GAYNOR RICHARD | director | 46568 0.0421% | $933,222.72 | 0 | 1 | |
| WIRTH PETER | director | 0 0% | $0 | 1 | 1 | <0.0001% |
$47,419,530 | 58 | 17.20% | $1.87B | |
$1,376,668 | 53 | 18.46% | $1.86B | |
$11,583,737 | 45 | 49.75% | $2.57B | |
$571,084,134 | 44 | 4.33% | $1.94B | |
$62,927,079 | 29 | 14.02% | $2.07B | |
$25,045,414 | 23 | -3.79% | $2.01B | |
$8,195,601 | 23 | -12.08% | $2.08B | |
$12,094,896 | 19 | 20.07% | $1.89B | |
$174,105,409 | 15 | 10.88% | $2.73B | |
$73,814,940 | 15 | -4.77% | $2.3B | |
$45,445,266 | 9 | -24.96% | $2.7B | |
$130,038,539 | 8 | 26.82% | $2.3B | |
$32,575,266 | 8 | 37.03% | $2.66B | |
$25,073,947 | 7 | -5.99% | $2.13B | |
$4,623,072 | 7 | 11.07% | $1.95B | |
$91,589,325 | 7 | -6.97% | $2.47B | |
Zai Lab Limited (ZLAB) | $666,380 | 5 | -16.60% | $2.22B |
$24,000,085 | 4 | 33.26% | $2.48B | |
$5,000,000 | 1 | -22.84% | $2.41B |
| Increased Positions | 68 | +33.66% | 7M | +16.26% |
| Decreased Positions | 92 | -45.54% | 17M | -42.36% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 48 | Sold Out | 9M | Sold Out |
| Total Postitions | 178 | -11.88% | 30M | -26.1% |
| Capital World Investors | $105,326.00 | 5.43% | 6.08M | +41,481 | +0.69% | 2025-09-30 |
| Fmr Llc | $81,481.00 | 4.2% | 4.7M | -1M | -24.13% | 2025-09-30 |
| Clearbridge Investments, Llc | $60,990.00 | 3.14% | 3.52M | -492,619 | -12.28% | 2025-09-30 |
| Rtw Investments, Lp | $39,709.00 | 2.05% | 2.29M | -3M | -58.62% | 2025-09-30 |
| Janus Henderson Group Plc | $35,518.00 | 1.83% | 2.05M | -148,323 | -6.75% | 2025-09-30 |
| Wellington Management Group Llp | $29,781.00 | 1.53% | 1.72M | +341,492 | +24.8% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $28,201.00 | 1.45% | 1.63M | +319,182 | +24.4% | 2025-09-30 |
| Bamco Inc /Ny/ | $23,764.00 | 1.22% | 1.37M | -216,571 | -13.64% | 2025-09-30 |
| Citadel Advisors Llc | $17,105.00 | 0.88% | 987,043 | +620,830 | +169.53% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $16,440.00 | 0.85% | 948,671 | +795,634 | +519.9% | 2025-09-30 |